已发表论文

基于适配子识别释放策略的SERS分析平台高效敏感诊断结直肠癌前病变

 

Authors Chen F, Huang Y, Liu Y, Zhuang Y, Cao X, Qin X

Received 12 August 2024

Accepted for publication 18 September 2024

Published 30 September 2024 Volume 2024:19 Pages 10009—10021

DOI https://doi.org/10.2147/IJN.S483261

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Yan Shen

Fengsong Chen,1,* Yanhua Huang,1,* Yongxia Liu,2 Yanwen Zhuang,3 Xiaowei Cao,3 Xiaogang Qin2 

1Department of Gastroenterology, Nantong Haimen People’s Hospital, Nantong, Jiangsu, 226100, People’s Republic of China; 2Department of gastroenterology, Traditional Chinese Medicine Hospital of Tongzhou District, Nantong, Jiangsu, 226300, People’s Republic of China; 3Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Xiaogang Qin, Email tzqinxiaogang@163.com

Background: Colorectal cancer (CRC) has become a significant global public health challenge, demanding immediate attention due to its high incidence and mortality rates. Regular CRC screening is essential for the early detection of precancerous lesions and CRC.
Methods: : We developed a novel surface-enhanced Raman scattering (SERS) analysis platform that employs high-throughput microarray chips as carriers and Au/SnO2 nanoring arrays (Au/SnO2 NRAs) as substrates. This platform utilizes an aptamer recognition-release strategy to achieve efficient and sensitive detection of protein tumor markers. In the detection process, the strong affinity and high specificity between the aptamer and the target protein result in competitive replacement of the SERS nanoprobes originally bound to the substrate surface. As a result, the SERS nanoprobes carrying Raman reporter genes are dislodged, leading to a reduction in the SERS signal intensity.
Results: The platform demonstrated excellent detection performance, with rapid detection completed within 15 minutes and limits of detection (LOD) as low as 6.2× 10− 12 g/mL for hnRNP A1 and 6.51× 10− 12 g/mL for S100P. Clinical samples analyzed using the SERS platform showed high consistency with enzyme-linked immunosorbent assay (ELISA) results.
Conclusion: This platform offers strong support for the early detection, risk assessment, and treatment monitoring of colorectal cancer precancerous lesions, with broad potential for clinical applications.

Keywords: colorectal cancer, precancerous lesions, surface enhanced raman scattering, aptamer, microarray chip